Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes

Neurology

Volumn 83, Issue 2, 2014, Pages 118-124

  Shahrizaila, Nortina ^a   Kokubun, Norito ^b   Sawai, Setsu ^c   Umapathi, Thirugnanam ^d   Chan, Yee Cheun ^e   Kuwabara, Satoshi ^c   Hirata, Koichi ^b   Yuki, Nobuhiro ^e  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d National Neuroscience Institute   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GANGLIOSIDE; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GM1; GANGLIOSIDE GQ 1B; GANGLIOSIDE GT 1A; GANGLIOSIDE GT 1B; GANGLIOSIDE LM1; GANGLIOTETRAOSYLCERAMIDE; GLYCOLIPID; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; IMMUNOGLOBULIN G;

ACUTE MOTOR AXONAL NEUROPATHY; ARTICLE; CLINICAL FEATURE; ELECTRODIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NERVE CONDUCTION; PRIORITY JOURNAL; CLASSIFICATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; IMMUNOLOGY; JAPAN; MALAYSIA; MOTOR NEURON DISEASE; PHYSIOLOGY; SINGAPORE;

AUTOANTIBODIES; COHORT STUDIES; CONFIDENCE INTERVALS; ELECTRODIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANGLIOSIDES; GLYCOLIPIDS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULIN G; JAPAN; MALAYSIA; MOTOR NEURON DISEASE; NEURAL CONDUCTION; SINGAPORE;

EID: 84903985531     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000577     Document Type: Article

References (33)

1. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118: 597-605.
2. Uncini A, Kuwabara S. Electrodiagnostic criteria for Guillain- Barré syndrome: a critical revision and the need for an update. Clin Neurophysiol 2012;123: 1487-1495.
3. Shahrizaila N, Yuki N. Antiganglioside antibodies in Guillain- Barré syndrome and its related conditions. Expert Rev Neurother 2011;11: 1305-1313.
4. Kaida K, Morita D, Kanzaki M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 2004;56: 567-571.
5. Kuwahara M, Suzuki S, Takada K, Kusunoki S. Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 2011;239: 87-90.
6. Kaida K, Sonoo M, Ogawa G, et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barré syndrome. Neurology 2008;71: 1683-1690.
7. Kaida K, Morita D, Kanzaki M, et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007;182: 212-218.
8. Yuki N, Shahrizaila N. Keeping it simple: is there a need for the various subtyping of axonal forms of Guillain-Barré syndrome? J Neurol Neurosurg Psychiatry 2011;82: 592.
9. Shahrizaila N, Goh KJ, Kokubun N, Abdullah S, Yuki N. Serial nerve conduction studies provide insight into the pathophysiology of Guillain-Barré and Fisher syndromes. J Neurol Sci 2011;309: 26-30.
10. Sekiguchi Y, Uncini A, Yuki N, et al. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study. J Neurol Neurosurg Psychiatry 2012;83: 23-28.
11. Ogawa-Goto K, Funamoto N, Ohta Y, Abe T, Nagashima K. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 1992;59: 1844-1849.
12. Svennerholm L, Bostrom K, Fredman P, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214: 115-123.
13. Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulfatide of peripheral-nerve myelin. J Neurol 1991;238: 75-79.
14. Ilyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SD. Antibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992;107: 111-121.
15. Susuki K, Yuki N, Hirata K, Kuwabara S. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome. J Neurol Sci 2002;195: 145-148.
16. Yuki N, Tagawa Y, Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1996;70: 1-6.
17. Yako K, Kusunoki S, Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain-Barré syndrome. J Neurol Sci 1999;168: 85-89.
18. Kuwabara S, Yuki N, Koga M, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome. Ann Neurol 1998;44: 202-208.
19. Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain 2010;133: 2897-2908.
20. Susuki K, Johkura K, Yuki N, Hasegawa O, Kuroiwa Y. Rapid resolution of nerve conduction blocks after plasmapheresis in Guillain-Barré syndrome associated with anti-GM1b IgG antibody. J Neurol 2001;248: 148-150.
21. Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A. Acute motor conduction block neuropathy: another Guillain-Barré syndrome variant. Neurology 2003;61: 617-622.
22. Shahrizaila N, Yuki N. Guillain-Barré syndrome animal model: the first proof of molecular mimicry in human autoimmune disorder. J Biomed Biotechnol 2011;2011: 829129.
23. Kaida K, Kusunoki S, Kanzaki M, Kamakura K, Motoyoshi K, Kanazawa I. Anti-GQ1b antibody as a factor predictive of mechanical ventilation in Guillain-Barré syndrome. Neurology 2004;62: 821-824.
24. Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64: 1519-1523.
25. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43: 1911-1917.
26. Mizoguchi K, Hase A, Obi T, et al. Two species of antiganglioside antibodies in a patient with a pharyngealcervical-brachial variant of Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1994;57: 1121-1123.
27. Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002;72: 767-771.
28. Yoshino H, Harukawa H, Asano A. IgG antiganglioside antibodies in Guillain-Barré syndrome with bulbar palsy. J Neuroimmunol 2000;105: 195-201.
29. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome. Philadelphia: F.A. Davis; 1991.
30. Ropper AH. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994;51: 671-675.
31. Susuki K, Atsumi M, Koga M, Hirata K, Yuki N. Acute facial diplegia and hyperreflexia: a Guillain-Barré syndrome variant. Neurology 2004;62: 825-827.
32. Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44: 780-788.
33. Rinaldi S, Brennan KM, Kalna G, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PloS One 2013;8: e82337.